Alimentary Pharmacology & Therapeutics, 56, 8, pp. 1250-1263 Alimentary Pharmacology & Therapeutics, 56, 1250-1263 Chanchlani, N, Lin, S, Auth, M K, Lee, C L, Robbins, H, Looi, S, Murugesan, S V, Riley, T, Preston, C, Stephenson, S, Cardozo, W, Sonwalkar, S A, Allah-ditta, M, Mansfield, L, Durai, D, Baker, M, London, I, London, E, Gupta, S, Di Mambro, A, Murphy, A, Gaynor, E, Jones, K D J, Claridge, A, Sebastian, S, Ramachandran, S, Selinger, C P, Borg-bartolo, S P, Knight, P, Sprakes, M B, Burton, J, Kane, P, Lupton, S, Fletcher, A, Gaya, D R, Colbert, R, Seenan, J P, Macdonald, J, Lynch, L, Mclachlan, I, Shields, S, Hansen, R, Gervais, L, Jere, M, Akhtar, M, Black, K, Henderson, P, Russell, R K, Lees, C W, Derikx, L A A P, Lockett, M, Betteridge, F, De Silva, A, Hussenbux, A, Beckly, J, Bendall, O, Hart, J W, Thomas, A, Hamilton, B, Gordon, C, Chee, D, Mcdonald, T J, Nice, R, Parkinson, M, Gardner-thorpe, H, Butterworth, J R, Javed, A, Al-shakhshir, S, Yadagiri, R, Maher, S, Pollok, R C G, Ng, T, Appiahene, P, Donovan, F, Lok, J, Chandy, R, Jagdish, R, Baig, D, Mahmood, Z, Marsh, L, Moss, A, Abdulgader, A, Kitchin, A, Walker, G J, George, B, Lim, Y, Gulliver, J, Bloom, S, Theaker, H, Carlson, S, Cummings, J R F, Livingstone, R, Beale, A, Carter, J O, Bell, A, Coulter, A, Snook, J, Stone, H, Kennedy, N A, Goodhand, J R & Ahmad, T 2022, ' Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF Therapy (IMSAT) therapeutic drug monitoring study ', Alimentary Pharmacology and Therapeutics, vol. 56, no. 8, pp. 1250-1263 . https://doi.org/10.1111/apt.17170, https://doi.org/10.1111/apt.v56.8
RECOVERY Collaborative Group 2023, ' Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. ', Lancet (London, England), vol. 401, no. 10387, pp. 1499-1507 . https://doi.org/10.1016/S0140-6736(23)00510-X
Mumford, A D & Gibbison, B J J 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 Dimitriadis, G K 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 RECOVERY Collaborative Group & Dark, P 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet . https://doi.org/10.1016/S0140-6736(22)01109-6
Lancet (London, England) LANCET RECOVERY Collaborative Group 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) a randomised controlled, open-label, platform trial ', The Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Mumford, A D 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised controlled, open-label, platform trial ', Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Group, RECOVERY C & Dark, P 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. ', Lancet (London, England), vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7
RECOVERY Collaborative Group & Downey, D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Mumford, A D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Lancet (London, England) Group, RECOVERY C, Felton, T, Dark, P & Mathioudakis, A 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5